Larimar Therapeutics Files 8-K on Financials & Other Events

Ticker: LRMR · Form: 8-K · Filed: Feb 12, 2024 · CIK: 1374690

Larimar Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyLarimar Therapeutics, Inc. (LRMR)
Form Type8-K
Filed DateFeb 12, 2024
Risk Levelmedium
Pages3
Reading Time3 min
Key Dollar Amounts$0.001, $86.8 million
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: financial-condition, corporate-update, 8-K

TL;DR

**Larimar Therapeutics just dropped an 8-K on financials and other events, so keep an eye out for details.**

AI Summary

Larimar Therapeutics, Inc. filed an 8-K on February 12, 2024, to report on its 'Results of Operations and Financial Condition' and 'Other Events.' This filing indicates that the company is providing an update on its financial status and other significant developments. For investors, this matters because it offers a current snapshot of the company's health and any recent material events that could impact its stock performance, allowing them to make informed decisions.

Why It Matters

This filing provides investors with crucial, up-to-date information on Larimar Therapeutics' financial performance and any recent material events, which can directly influence the stock's valuation and future prospects.

Risk Assessment

Risk Level: medium — The filing itself is routine, but the content it refers to (financial results and other events) could contain information that significantly impacts the company's risk profile.

Analyst Insight

Investors should review the full content of the 8-K filing, particularly the sections on 'Results of Operations and Financial Condition' and 'Other Events,' to understand the specific financial updates and any material developments that could impact Larimar Therapeutics' stock.

Key Numbers

  • 001-36510 — Commission File Number (identifies the company's registration with the SEC)
  • 20240212 — Date of Report (the date the earliest event reported in the 8-K occurred)
  • 844-511-9056 — Registrant's Telephone Number (contact information for Larimar Therapeutics, Inc.)
  • 19004 — Zip Code (part of Larimar Therapeutics' principal executive offices address)
  • 20100301 — Date of Name Change (when ZAFGEN, INC. changed its name)

Key Players & Entities

  • Larimar Therapeutics, Inc. (company) — the registrant filing the 8-K
  • Delaware (company) — state of incorporation for Larimar Therapeutics, Inc.
  • Nasdaq Global Market (company) — exchange where Larimar Therapeutics' Common Stock is registered
  • ZAFGEN, INC. (company) — former name of Larimar Therapeutics, Inc.
  • $0.001 (dollar_amount) — par value per share of Common Stock

Forward-Looking Statements

  • Larimar Therapeutics will release detailed financial results for the period ending December 31, 2023, shortly after this 8-K filing. (Larimar Therapeutics, Inc.) — high confidence, target: 2024-03-31
  • The 'Other Events' section of this 8-K will disclose a significant corporate development, such as a new clinical trial update or partnership. (Larimar Therapeutics, Inc.) — medium confidence, target: 2024-02-12

FAQ

What is the primary purpose of this 8-K filing by Larimar Therapeutics, Inc.?

The primary purpose of this 8-K filing by Larimar Therapeutics, Inc. is to report on 'Results of Operations and Financial Condition' and 'Other Events' as of February 12, 2024.

What is the trading symbol and the exchange where Larimar Therapeutics, Inc.'s common stock is registered?

Larimar Therapeutics, Inc.'s common stock trades under the symbol 'lrmr' and is registered on the Nasdaq Global Market.

What was the former name of Larimar Therapeutics, Inc. and when did one of its name changes occur?

One of the former names of Larimar Therapeutics, Inc. was ZAFGEN, INC., and a name change occurred on March 1, 2010 (20100301).

What is the par value per share of Larimar Therapeutics, Inc.'s Common Stock?

The par value per share of Larimar Therapeutics, Inc.'s Common Stock is $0.001.

Where are Larimar Therapeutics, Inc.'s principal executive offices located?

Larimar Therapeutics, Inc.'s principal executive offices are located at Three Bala Plaza East, Bala Cynwyd, Pennsylvania, 19004.

Filing Stats: 816 words · 3 min read · ~3 pages · Grade level 11.4 · Accepted 2024-02-12 07:03:55

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share lrmr Nasdaq Global Market
  • $86.8 million — 31, 2023, the Company had approximately $86.8 million of cash, cash equivalents and marketabl

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On February 12, 2024, Larimar Therapeutics, Inc. (the " Company ") announced that, as of December 31, 2023, the Company had approximately $86.8 million of cash, cash equivalents and marketable securities. This unaudited, preliminary amount has been prepared by and is the responsibility of management. This amount is based upon information available to management as of the date of this Current Report on Form 8-K and subject to completion of financial closing procedures that could result in changes to the amount. Furthermore, this amount does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2023. The Company's independent registered public accounting firm, PricewaterhouseCoopers LLP, has not audited, reviewed, compiled or performed any procedures with respect to this preliminary financial data and, accordingly, PricewaterhouseCoopers LLP does not express an opinion or any other form of assurance with respect thereto. The Company's actual results for the year ended December 31, 2023 will be included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 and may differ materially from the above estimate. The information furnished pursuant to this Item 2.02 is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. Press Release On February 12, 2024, the Company issued a press release announcing top-line data and successful completion of its four-week, placebo-controlled Phase 2 dose exploration study of nomlabofusp (CTI-1601) in participants with Friedreich's ataxia. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Investor Presentations On February 12, 2024, the Company posted on its website two slide presentations, which are attached as Exhibit 99.2 and 99.3 to this Current Report on Form 8-K and are incorporated herein by reference. Representatives of the Company will use these presentations in various meetings with investors, analysts and other parties from time to time.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Below is a list of exhibits included with this Current Report on Form 8-K. Exhibit No. Document 99.1 Press Release issued by Larimar Therapeutics, Inc. on February 12, 2024* 99.2 Larimar Therapeutics, Inc. Corporate Presentation, dated February 12, 2024* 99.3 Larimar Therapeutics, Inc. Program Update Presentation, dated February 12, 2024* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Larimar Therapeutics, Inc. Date: February 12, 2024 By: /s/ Carole S. Ben-Maimon, M.D. Name: Carole S. Ben-Maimon, M.D. Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.